Education
About Us
Working with TipRanks
Follow Us
Quanterix (QTRX)
:QTRX
QTRX Analyst Ratings
Hold
1 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
QTRX Stock 12 Month Forecast
Average Price Target
$8.50
▲(44.31%Upside)
| Highest Price Target$12.00 | Average Price Target$8.50 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$7
Hold
18.85%
Upside
Reiterated
07/10/25
Quanterix's overall stock score is driven by the strategic initiatives and potential synergies from the Akoya Biosciences acquisition, which are promising for long-term growth. However, current financial performance and valuation challenges weigh down the score, with negative cash flows and profitability concerns being significant factors.
Canaccord Genuity
$12
Buy
103.74%
Upside
Reiterated
06/17/25
Leerink Partners
―
Hold
―
Reiterated
06/02/25
Leerink Partners Remains a Hold on Quanterix (QTRX)We remain cautious on the deal, given it adds integration risks to an already challenging macro backdrop and reduces cash flexibility for QTRX in 2026. Recall, QTRX expects to have $160M in cash post-close and $120M by YE25, compared to $267M in cash at the end of 1Q25. We also see risks to QTRX continuing to fall behind in the $9B Alzheimer's Dx market (LP estimate), with Fujirebio (part of HU Lumipulse already obtaining an FDA approval for its test and Roche (RHHBY, Not Rated) planning to file for its pTau217 test in 2026. We believe QTRX is currently on track to FDA approval of its multi-marker test in 2026, but will need meaningful commercial investment to drive the adoption. The AKYA-QTRX deal is expected to close in 2Q25, with the AKYA shareholder vote likely in late June.
TD Cowen
$7.5→$7
Hold
18.85%
Upside
Reiterated
05/12/25
Scotiabank
$28→$18
Buy
205.60%
Upside
Reiterated
03/25/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$7
Hold
18.85%
Upside
Reiterated
07/10/25
Quanterix's overall stock score is driven by the strategic initiatives and potential synergies from the Akoya Biosciences acquisition, which are promising for long-term growth. However, current financial performance and valuation challenges weigh down the score, with negative cash flows and profitability concerns being significant factors.
Canaccord Genuity
$12
Buy
103.74%
Upside
Reiterated
06/17/25
Leerink Partners
―
Hold
―
Reiterated
06/02/25
Leerink Partners Remains a Hold on Quanterix (QTRX)We remain cautious on the deal, given it adds integration risks to an already challenging macro backdrop and reduces cash flexibility for QTRX in 2026. Recall, QTRX expects to have $160M in cash post-close and $120M by YE25, compared to $267M in cash at the end of 1Q25. We also see risks to QTRX continuing to fall behind in the $9B Alzheimer's Dx market (LP estimate), with Fujirebio (part of HU Lumipulse already obtaining an FDA approval for its test and Roche (RHHBY, Not Rated) planning to file for its pTau217 test in 2026. We believe QTRX is currently on track to FDA approval of its multi-marker test in 2026, but will need meaningful commercial investment to drive the adoption. The AKYA-QTRX deal is expected to close in 2Q25, with the AKYA shareholder vote likely in late June.
TD Cowen
$7.5→$7
Hold
18.85%
Upside
Reiterated
05/12/25
Scotiabank
$28→$18
Buy
205.60%
Upside
Reiterated
03/25/25
Best Analysts Covering Quanterix
1 Month
xxx
Success Rate
7/19 ratings generated profit
Average Return
-4.82%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 36.84% of your transactions generating a profit, with an average return of -4.82% per trade.
3 Months
xxx
Success Rate
4/19 ratings generated profit
Average Return
-14.66%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 21.05% of your transactions generating a profit, with an average return of -14.66% per trade.
1 Year
Success Rate
4/19 ratings generated profit
Average Return
-34.06%
reiterated a buy rating 4 months ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 21.05% of your transactions generating a profit, with an average return of -34.06% per trade.
2 Years
xxx
Success Rate
6/19 ratings generated profit
Average Return
-18.47%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 31.58% of your transactions generating a profit, with an average return of -18.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
QTRX Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
5
6
5
3
2
Buy
3
2
0
0
0
Hold
2
4
8
10
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
12
13
13
11
Each month's total comprises the sum of three months' worth of ratings.
QTRX Financial Forecast
QTRX Stock Forecast FAQ
What is QTRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Quanterix’s 12-month average price target is 8.50.
What is QTRX’s upside potential, based on the analysts’ average price target?
Quanterix has 44.31% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is QTRX a Buy, Sell or Hold?
Quanterix has a consensus rating of Hold which is based on 1 buy ratings, 4 hold ratings and 0 sell ratings.
What is Quanterix’s price target?
The average price target for Quanterix is 8.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $7.00. The average price target represents 44.31% Increase from the current price of $5.89.
The highest analyst price target is $12.00 ,the lowest forecast is $7.00. The average price target represents 44.31% Increase from the current price of $5.89.
What do analysts say about Quanterix?
Quanterix’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of QTRX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.